Physician profile
Edwin Choy
NPI 1760466106
$17,312.60
in general payments reported to CMS, 2019-2025
16 companies · $606 in 2025
The $606 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,613 · 2021: $5,199 · 2024: $9,895 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,504 · Consulting Fee: $3,360 · Honoraria: $1,755 · Food and Beverage: $1,040 · Travel and Lodging: $842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,504.00 |
| Consulting Fee | $3,360.00 |
| Honoraria | $1,755.00 |
| Food and Beverage | $1,039.90 |
| Travel and Lodging | $842.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $4,612.50 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $3,737.79 | 2024-2025 | Tazverik |
| Springworks Therapeutics, INC. | $3,360.00 | 2024 | Ogsiveo |
| Deciphera Pharmaceuticals INC. | $2,764.20 | 2024 | Vimseltinib |
| Bayer Healthcare Pharmaceuticals INC. | $2,100.00 | 2021 | |
| Icotec Medical INC. | $436.64 | 2025 | Kong-Tl Vbr E, Expandable Body, L, 19 Mm X 27 - 37 Mm, Kong-Tl Vbr, End Plate, Round, L and Screw, 12 X 43 Mm, Vader Pedicle System, Rod, Carbon/Peek, Curved, 6.0 R450 X 200 Mm |
| Tempus Ai, INC | $113.75 | 2024 | Xt Cdx |
| Epizyme, INC. | $99.00 | 2021 | |
| Aadi Bioscience, INC. | $88.72 | 2024 | Fyarro |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Choy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.